GSK's Bepirovirsen NDA Accepted for Review in China for Chronic Hepatitis B
GSK sits 68% above its 52-week low of $32.38.
Summary
GSK announced that China's NMPA has accepted its New Drug Application for bepirovirsen, a potential first-in-class functional cure for chronic hepatitis B, supported by positive Phase III trial results.
Key Events · Product Development and Regulatory · GSK
-
Regulatory Acceptance in China
China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for bepirovirsen for the treatment of adults with chronic hepatitis B (CHB).
-
Potential First-in-Class Functional Cure
Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed as a potential first-in-class functional cure for CHB, a condition with low functional cure rates from current standard of care.
-
Significant Market Opportunity
Chronic hepatitis B affects an estimated 75 million people in China, representing a substantial patient population for this potential new treatment.
-
Supported by Positive Phase III Data
The regulatory submission is backed by statistically significant and clinically meaningful functional cure rates demonstrated in the pivotal Phase III B-Well 1 and B-Well 2 trials.
Analysis · GSK · Life Sciences
This filing marks a significant regulatory advancement for GSK's bepirovirsen in a critical market, following its recent acceptance for review by the EMA. The drug, which has Breakthrough Therapy designation in China, targets chronic hepatitis B, a condition affecting an estimated 75 million people in China with high mortality rates. The NDA acceptance, based on strong Phase III data, positions bepirovirsen as a potential first-in-class functional cure, offering a significant improvement over current treatments that have low functional cure rates. This development enhances GSK's pipeline value and future revenue potential in a large, underserved patient population.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $54.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $108.6B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.